Last updated: September 30, 2026
Brexpiprazole, marketed as Rexulti by Otsuka Pharmaceutical and Lundbeck, has developed from a schizophrenia and major depressive disorder product into a broader central-nervous-system franchise. The FDA’s 2023 approval for agitation associated with Alzheimer’s dementia expanded the addressable market and extended commercial momentum. U.S. sales growth has been driven primarily by adjunctive major depressive disorder use and the Alzheimer’s agitation indication, while patent and Paragraph IV activity create a medium-term generic-entry risk for the oral tablets.
What is brexpiprazole and how is Rexulti used?
Brexpiprazole is an orally administered atypical antipsychotic. It is a dopamine D2 and serotonin 5-HT1A partial agonist and a serotonin 5-HT2A antagonist. Rexulti is approved in the United States for:
| Indication |
FDA status |
Commercial relevance |
| Schizophrenia in adults |
Approved July 2015 |
Established base market |
| Adjunctive treatment of major depressive disorder in adults |
Approved July 2015 |
Largest growth driver |
| Agitation associated with dementia due to Alzheimer’s disease |
Approved May 2023 |
New expansion market |
The Alzheimer’s indication is important because it gives Rexulti access to a large population with limited approved pharmacologic options. The approval carries the class boxed warning for increased mortality in elderly patients with dementia-related psychosis. Rexulti is not approved for treating dementia-related psychosis itself; its approved use is agitation associated with Alzheimer’s dementia. [1]
Brexpiprazole competes with other atypical antipsychotics, including aripiprazole, quetiapine, olanzapine, risperidone, cariprazine and lumateperone. In depression, it competes with branded and generic adjunctive therapies. In Alzheimer’s agitation, its competitive set includes nonpharmacologic interventions, off-label antipsychotic use and other emerging therapies.
How large is the Rexulti market?
Rexulti has become one of Lundbeck’s largest products and a material contributor to Otsuka’s U.S. pharmaceutical business. Lundbeck reports product revenue in Danish kroner, while Otsuka reports consolidated and segment results under its corporate reporting structure.
Rexulti sales trajectory
| Year |
Reported Rexulti revenue indicator |
Market interpretation |
| 2015 |
Initial U.S. launch |
Limited first-year base |
| 2018 |
More than DKK 2 billion for Lundbeck |
Mature schizophrenia and depression uptake |
| 2021 |
Continued double-digit growth |
Expansion in major depressive disorder |
| 2022 |
Approximately DKK 3.5 billion for Lundbeck |
Strong pre-Alzheimer’s growth |
| 2023 |
Approximately DKK 4.2 billion for Lundbeck |
Alzheimer’s approval and continued U.S. demand |
| 2024 |
Approximately DKK 5 billion range for Lundbeck |
Full-year contribution from the new indication |
The exact economic split between Otsuka and Lundbeck is not equivalent to the reported Lundbeck product-revenue figure. The companies commercialize the product through regional arrangements, and each reports revenue under its own accounting framework. Lundbeck identifies Rexulti as a strategic growth product in its annual reports, while Otsuka reports the product within its pharmaceutical portfolio. [2,3]
The revenue trajectory has been supported by four factors:
- Continued prescribing in major depressive disorder as adjunctive therapy.
- Increased physician familiarity with brexpiprazole relative to newer branded antipsychotics.
- The 2023 Alzheimer’s agitation approval.
- Expansion of the treated population without a corresponding loss of the core schizophrenia business.
Rexulti’s growth profile differs from that of a conventional primary-care product. Prescribing is concentrated among psychiatrists, neurologists, geriatric specialists and institutional-care providers. Reimbursement, prior authorization and boxed-warning considerations remain important commercial constraints.
When does brexpiprazole lose U.S. exclusivity?
Brexpiprazole’s principal U.S. composition-of-matter protection is associated with U.S. Patent No. 7,888,362. The patent covers brexpiprazole and related chemical subject matter and has a nominal expiration in 2026, subject to applicable patent-term adjustment or extension. The FDA’s Orange Book must be consulted for the current listed patent set and any pediatric exclusivity effect. [4,5]
Brexpiprazole exclusivity timeline
| Event |
Date |
| U.S. patent priority period for brexpiprazole chemistry |
Mid-2000s |
| U.S. Patent No. 7,888,362 issued |
February 2011 |
| FDA approval of Rexulti |
July 2015 |
| MDD supplemental approval |
July 2015 |
| Alzheimer’s agitation approval |
May 2023 |
| Core composition patent nominal expiry |
2026 |
| Expected first meaningful generic risk |
2026 onward, subject to litigation and settlement terms |
The Alzheimer’s approval did not create a new chemical entity exclusivity period. It generated regulatory and commercial expansion but did not reset the original composition patent term. The new indication may be protected by method-of-use patents, but method patents do not necessarily prevent an ANDA applicant from launching with a label that omits the patented use.
What patents protect Rexulti and brexpiprazole formulations?
The Rexulti estate has several potential layers:
- Composition-of-matter patents covering brexpiprazole.
- Solid-state, crystalline or polymorph patents.
- Pharmaceutical-composition and tablet-formulation patents.
- Method-of-use patents covering psychiatric and neurologic indications.
- Patents directed to dosing or patient-selection approaches.
The composition patent is the strongest conventional barrier because it covers the active molecule rather than a particular indication. Formulation and method patents can extend the estate, but their value depends on claim scope, Orange Book listing, enforceability and whether an ANDA product practices the claimed subject matter.
A generic manufacturer may challenge the composition patent through a Paragraph IV certification. It may also certify that a listed method-of-use patent is not infringed, is invalid or is unenforceable. For a drug with multiple indications, a section viii “skinny label” strategy can reduce method-of-use exposure, although it does not eliminate the risk of induced-infringement litigation.
Which companies are challenging brexpiprazole patents?
Generic manufacturers have shown interest in brexpiprazole through ANDA activity and Paragraph IV litigation. Teva Pharmaceuticals has been publicly associated with a brexpiprazole patent dispute involving Otsuka and Lundbeck. The commercial significance of that dispute depends on the patents asserted, the dosage forms covered and the settlement or judgment terms.
A Paragraph IV filing does not mean immediate generic launch. The first applicant may receive 180 days of shared or exclusive generic-launch economics, but launch can be delayed by:
- A 30-month statutory stay after patent litigation is filed.
- A court injunction.
- A settlement restricting launch.
- Regulatory deficiencies in the ANDA.
- Patent claims that survive validity or infringement challenges.
The relevant diligence question is not simply whether an ANDA has been filed. It is whether a generic applicant has obtained a final judgment, reached a license date, or secured a settlement permitting launch before the principal patent expiry.
What is the Orange Book status of Rexulti?
Rexulti tablets are listed in the FDA Orange Book under brexpiprazole. Orange Book-listed patents can trigger the Hatch-Waxman 30-month stay when the brand owner files an infringement action following a Paragraph IV notice.
The key Orange Book issues are:
| Issue |
Impact |
| Listed composition patent |
Can delay approval and block launch until expiry or successful challenge |
| Listed formulation patent |
May support litigation but can be narrower than composition protection |
| Listed method-of-use patent |
May be avoided through a section viii statement or skinny label |
| Pediatric exclusivity |
Can add six months to otherwise qualifying patent protection |
| Patent delisting or correction |
Can alter litigation timing and approval constraints |
Orange Book status should be evaluated at the product-and-strength level. A patent listed for one strength or indication may not apply identically to every commercial presentation. [4]
How strong is the brexpiprazole patent estate?
The estate is strongest through the 2026 composition-patent period and weaker afterward unless formulation or method patents provide enforceable additional protection.
Patent-strength assessment
| Protection layer |
Relative strength |
Reason |
| Composition of matter |
High before expiry |
Broad coverage of the active ingredient |
| Formulation |
Moderate |
Depends on claim breadth and generic product design |
| Polymorph or solid-state |
Moderate |
Can be designed around or attacked on validity grounds |
| Method of use |
Moderate to low against skinny labels |
Generic may omit patented indications |
| Manufacturing process |
Moderate |
Often avoidable through alternative processes |
| Trade secrets and know-how |
Moderate |
Can slow development but rarely prevents generic approval |
Brexpiprazole is a small molecule, so it does not face biosimilar substitution rules. Generic risk is therefore more direct than for an originator biologic. Once relevant patents and regulatory exclusivities expire, an ANDA-approved tablet can generally enter through the conventional generic pathway.
What patent litigation affects Rexulti generic entry?
The primary litigation risk concerns Hatch-Waxman challenges to listed patents. Otsuka and Lundbeck can sue after receiving a Paragraph IV notice, creating the statutory stay. The case may address invalidity, noninfringement, patent eligibility, written description, enablement and obviousness.
The commercial outcome may fall into four categories:
- Brand victory with launch delayed until patent expiry.
- Generic victory with accelerated entry.
- Settlement permitting entry on a negotiated date.
- Settlement allowing an authorized generic or other supply arrangement.
Settlement terms are particularly important for forecasting because they can move effective generic entry ahead of nominal patent expiry. A negotiated launch date can also vary by dosage strength or indication.
What generic launch scenarios exist for brexpiprazole?
Scenario 1: Entry near core patent expiry
This is the baseline scenario if the composition patent remains enforceable through 2026 and no settlement accelerates launch. Multiple ANDA applicants could enter after the first filer’s exclusivity period, leading to rapid price erosion.
Scenario 2: Earlier settlement-based entry
A settlement could allow one or more generics to launch before the nominal expiry date. The impact would depend on the number of licensees and whether an authorized generic is launched.
Scenario 3: Limited indication entry
A generic could enter with schizophrenia and depression indications while omitting Alzheimer’s agitation if a method-of-use patent remains enforceable. This would reduce, but not eliminate, substitution risk.
Scenario 4: Delayed or blocked entry
A successful patent judgment, injunction or regulatory delay could preserve branded revenue beyond 2026. This scenario is less durable if the core composition protection expires and several generic applicants are ready to launch.
How does Rexulti compare with competing antipsychotics?
| Product |
Active ingredient |
Market status |
Generic or biosimilar risk |
| Rexulti |
Brexpiprazole |
Branded, expanding Alzheimer’s use |
Future ANDA risk |
| Abilify |
Aripiprazole |
Generic competition established |
High price pressure |
| Vraylar |
Cariprazine |
Branded growth product |
Later-stage patent risk |
| Caplyta |
Lumateperone |
Branded CNS product |
Patent-dependent |
| Seroquel |
Quetiapine |
Generic |
Mature low-price market |
| Latuda |
Lurasidone |
Generic competition established |
High price pressure |
Rexulti’s commercial advantage is the combination of established psychiatric use and a newer Alzheimer’s agitation indication. Its disadvantage is exposure to the same generic substitution mechanics that affected Abilify and other oral antipsychotics.
What is the regulatory and commercial outlook for brexpiprazole?
The FDA’s Alzheimer’s agitation approval creates the largest incremental growth opportunity, but uptake will be constrained by safety monitoring, payer controls and the boxed warning. Clinical adoption is likely to be concentrated in patients with clinically significant agitation for whom nonpharmacologic management is inadequate.
The product’s financial trajectory should be modeled in two phases:
- Pre-generic phase: continued growth from Alzheimer’s agitation and stable MDD demand.
- Post-generic phase: rapid erosion in tablet revenue, moderated by indication-specific patents, authorized-generic strategy, contracting and geographic differences.
Revenue exposure is concentrated in the United States because the U.S. market has the broadest label and highest branded pricing. European and other international markets may face different patent expiry dates, reimbursement conditions and generic-launch timing. A global forecast should not apply the U.S. expiry date uniformly across jurisdictions.
Are biosimilars a risk to Rexulti?
No. Brexpiprazole is a chemically synthesized small molecule, not a biologic. The relevant competitive threat is an FDA-approved generic under the ANDA pathway, not a biosimilar under the Public Health Service Act.
The principal risks are therefore:
- Paragraph IV patent challenges.
- Generic tablet approval after core patent expiry.
- Formulary substitution.
- Price discounting by multiple ANDA holders.
- Indication-specific label carving.
What licensing deal supports Rexulti commercialization?
Otsuka and Lundbeck entered a global collaboration covering central-nervous-system compounds, including brexpiprazole. The alliance combined Otsuka’s discovery and development capabilities with Lundbeck’s CNS commercialization infrastructure. The parties have commercialized Rexulti through regional rights and financial-sharing arrangements. [6]
The collaboration reduces single-company commercialization risk but also means revenue and profit contribution must be assessed separately for each partner. It is not appropriate to treat Lundbeck’s Rexulti revenue as the total global product revenue.
Key Takeaways
- Rexulti is brexpiprazole, an atypical antipsychotic marketed by Otsuka and Lundbeck.
- FDA approvals cover schizophrenia, adjunctive major depressive disorder and Alzheimer’s dementia-related agitation.
- The 2023 Alzheimer’s approval materially expanded the product’s commercial opportunity.
- Lundbeck’s Rexulti revenue increased from roughly DKK 3.5 billion in 2022 to approximately DKK 4.2 billion in 2023 and the DKK 5 billion range in 2024.
- U.S. composition-patent protection is centered on U.S. Patent No. 7,888,362, with nominal expiry in 2026, subject to applicable term adjustments or extensions.
- Teva and other generic manufacturers create Paragraph IV and Hatch-Waxman litigation risk.
- Formulation and method-of-use patents may delay or narrow generic entry but are weaker than composition protection.
- Brexpiprazole has generic risk, not biosimilar risk.
- The highest-value forecast variable is the effective U.S. generic launch date, including any settlement-based entry.
- Revenue is likely to remain strong before generic entry, followed by potentially rapid erosion once multiple ANDA products reach the market.
FAQs
Is Rexulti protected by a new patent for Alzheimer’s agitation?
The Alzheimer’s indication may be covered by method-of-use patents, but the 2023 FDA approval did not create a new chemical entity exclusivity period. The commercial effect depends on Orange Book listing and enforceability.
Can a generic brexpiprazole launch for depression but not Alzheimer’s agitation?
Yes. A generic applicant may attempt a section viii statement or use a label that omits a patented indication, subject to FDA requirements and litigation risk.
Will Rexulti face the same erosion as Abilify?
Rexulti is exposed to similar small-molecule generic substitution mechanics. Erosion could be moderated if method patents, settlement terms or limited initial generic entry restrict the approved label.
Which Rexulti indication is most important for long-term valuation?
The Alzheimer’s agitation indication has the greatest incremental market potential, while adjunctive major depressive disorder remains central to the existing revenue base.
Does the Otsuka-Lundbeck collaboration continue after U.S. patent expiry?
The collaboration can continue after patent expiry, but the economic value of the alliance will depend on generic timing, regional rights, authorized-generic arrangements and post-expiry pricing.
References
- U.S. Food and Drug Administration. (2023). Rexulti (brexpiprazole) prescribing information.
- H. Lundbeck A/S. (2023). Annual report 2023.
- Otsuka Holdings Co., Ltd. (2024). Integrated report and financial results materials.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- United States Patent and Trademark Office. (2011). U.S. Patent No. 7,888,362: Quinoline derivative.
- H. Lundbeck A/S and Otsuka Pharmaceutical Co., Ltd. (2011). Global CNS collaboration announcement.
